Pfizer moving to 3-dose trial for kids after 2-shot vaccine fails
Pfizer-BioNTech announced Friday its two-shot vaccine didn’t perform adequately in children ages 2 to 5 years old, and it will test a three-dose series for official authorization.
The pharmaceutical companies said they will expand ongoing clinical trials of their COVID-19 vaccine in children to include a third dose for participants as young as 6 months old, NPR reported.
Healthy children have, statistically, virtually no chance of death or hospitalization from a COVID-19 infection, according to data from the Centers for Disease Control.
The decision, the companies said, was made “following a routine review by the external independent Data Monitoring Committee,” which acts as a watchdog over the clinical trials.
They insisted, however, that no “safety concerns” were identified, and the 3 microgram doses “demonstrated a favorable safety profile in children 6 months to under 5 years of age.”- READ MORE
Responses